CY1124253T1 - Φαρμακευτικη συνθεση που περιεχει δαρουναβιρη και μεθοδος για την παρασκευη αυτης - Google Patents

Φαρμακευτικη συνθεση που περιεχει δαρουναβιρη και μεθοδος για την παρασκευη αυτης

Info

Publication number
CY1124253T1
CY1124253T1 CY20211100557T CY211100557T CY1124253T1 CY 1124253 T1 CY1124253 T1 CY 1124253T1 CY 20211100557 T CY20211100557 T CY 20211100557T CY 211100557 T CY211100557 T CY 211100557T CY 1124253 T1 CY1124253 T1 CY 1124253T1
Authority
CY
Cyprus
Prior art keywords
preparation
pharmaceutical composition
composition containing
darunavir
containing darunavir
Prior art date
Application number
CY20211100557T
Other languages
English (en)
Inventor
Evangelos Karavas
Efthymios Koutris
Vasiliki SAMARA
Ioanna Koutri
Anastasia Kalaskani
Christina KIZIRIDI
Morfis Abatzis
Original Assignee
Pharmathen S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmathen S.A. filed Critical Pharmathen S.A.
Publication of CY1124253T1 publication Critical patent/CY1124253T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με ένα φαρμακευτικό σκεύασμα άμεσης απελευθέρωσης που περιέχει Δαρουναβίρη. Επίσης σχετίζεται με μια μέθοδο παρασκευής αυτού.
CY20211100557T 2015-12-02 2021-06-23 Φαρμακευτικη συνθεση που περιεχει δαρουναβιρη και μεθοδος για την παρασκευη αυτης CY1124253T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GR20150100526A GR1008965B (el) 2015-12-02 2015-12-02 Φαρμακευτικο σκευασμα που περιλαμβανει δαρουναβιρη και μεθοδος παρασκευης αυτου
PCT/EP2016/025158 WO2017092874A1 (en) 2015-12-02 2016-11-30 Pharmaceutical composition comprising darunavir and method for the preparation thereof

Publications (1)

Publication Number Publication Date
CY1124253T1 true CY1124253T1 (el) 2022-07-22

Family

ID=57517848

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100557T CY1124253T1 (el) 2015-12-02 2021-06-23 Φαρμακευτικη συνθεση που περιεχει δαρουναβιρη και μεθοδος για την παρασκευη αυτης

Country Status (13)

Country Link
EP (1) EP3383402B1 (el)
CY (1) CY1124253T1 (el)
DK (1) DK3383402T3 (el)
ES (1) ES2875405T3 (el)
GR (1) GR1008965B (el)
HR (1) HRP20210969T1 (el)
HU (1) HUE054502T2 (el)
LT (1) LT3383402T (el)
PL (1) PL3383402T3 (el)
PT (1) PT3383402T (el)
RS (1) RS61955B1 (el)
SI (1) SI3383402T1 (el)
WO (1) WO2017092874A1 (el)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4912309B2 (ja) * 2004-09-02 2012-04-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ４−［［４−［［４−（２−シアノエテニル）−２，６−ジメチルフェニル］アミノ］−２−ピリミジニル］アミノ］ベンゾニトリルの塩酸塩
GB201118182D0 (en) * 2011-10-21 2011-12-07 Jagotec Ag Improvements in or relating to organic compounds
WO2013108105A2 (en) * 2012-01-18 2013-07-25 Aurobindo Pharma Limited Novel solvates of darunavir

Also Published As

Publication number Publication date
EP3383402A1 (en) 2018-10-10
DK3383402T3 (da) 2021-06-28
WO2017092874A1 (en) 2017-06-08
HUE054502T2 (hu) 2021-09-28
LT3383402T (lt) 2021-06-25
PL3383402T3 (pl) 2021-10-18
PT3383402T (pt) 2021-06-04
HRP20210969T1 (hr) 2021-09-17
SI3383402T1 (sl) 2021-08-31
GR1008965B (el) 2017-02-28
ES2875405T3 (es) 2021-11-10
EP3383402B1 (en) 2021-03-24
RS61955B1 (sr) 2021-07-30

Similar Documents

Publication Publication Date Title
CL2020001048A1 (es) Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281)
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112018010211A2 (pt) formulação farmacêutica aquosa compreendendo anticorpo anti-pd-l1 avelumab
BR112018010720A8 (pt) agonistas do receptor de apelina e métodos de uso
DOP2018000059A (es) Composiciones de insulina de rápida acción
CY1119489T1 (el) Υποκατεστημενη πιπεριδυλο-αιθυλο-πυριμιδινη ως αναστολεας της ο-ακυλο τρανσφερασης της γκρελινης
CU20180001A7 (es) Derivados de oxopiridina sustituidos y procesos para su preparación
CO2018003452A2 (es) Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso
PH12015502331A1 (en) Formulations of oxabicycloheptanes and oxabicycloheptenes
MX2017004975A (es) Composiciones de anticuerpos anti-il-7r.
EA201790650A1 (ru) Лекарственная форма и способы применения абиратерона ацетата
PH12016501686A1 (en) Pharmaceutical compositions of sitagliptin
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
MX2019002057A (es) Formas solidas de mesilato de cenicriviroc y procesos para elaborar formas sólidas de mesilato de cenicriviroc.
TR201821116A2 (tr) POSAKONAZOL İÇEREN FARMASÖTİK BİLEŞİMLER ve ÜRETİM YÖNTEMİ
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
CL2017000587A1 (es) Derivados de tetrahidroquinolina como inhibidores de bromodominio
MX2019005855A (es) Formulaciones que se pueden pulverizar.
CY1122578T1 (el) Φαρμακευτικο σκευασμα το οποιο περιλαμβανει αντισωμα
BR112017015159A2 (pt) preparação e uso de produtos plaquetários
CY1121105T1 (el) Φαρμακοτεχνικη μορφη αταζαναβιρης και κομπισιστατης για θεραπεια hiv
BR112017025427A2 (pt) composição farmacêutica oral
CY1117210T1 (el) Παραγωγα 2-οξο-1-ιμιδαζολιδινυλ ιμιδαζοθειαδιαζολης
CY1123877T1 (el) Μορφες στερεας καταστασης αλατων νιλοτινιμπης
IN2014CH00840A (el)